GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

Orchard Therapeutics, a UK-based gene therapy developer which counts pharmaceutical firm GlaxoSmithKline (GSK) as its second largest investor, floated in the US yesterday in a $200m initial public offering. The IPO consisted of almost 14.3 million American depositary shares (ADSs), each representing a single ordinary share, issued on the Nasdaq Global Select Market and priced…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.